A novel treatment, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in individuals with ...

Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

Most people assume that when blood pressure stays high despite medication, it’s due to stress or an incorrect dose. But resistant hypertension is a specific clinical condition. It means one’s blood ...

The following is a summary of “Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare—the DEMONSTRATE database,” published in the April 2025 ...

In a country where nearly 1 in 3 adults silently battles high blood pressure , the need for regular blood pressure monitoring ...

Do you know someone with high blood pressure? You probably do—it’s one of the most common health problems in the world. Also ...

A new medication called lorundrostat has shown strong potential as a treatment for people with uncontrolled or resistant high ...

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the ...

Renin content and mRNA were 77% and 65±5% of WT. Plasma aldosterone (in picograms per mL) was also significantly reduced (420±36 in β1/β2ADR −/− versus 692±59 in WT). A low-salt diet (0.03%) for 1 ...